2018
Roche acquired Flatiron Health in February for $2.1 billion, according to host Luke Timmerman.
“Flatiron was acquired by Roche in February for $2.1 billion.”
Topic
Roche is a Swiss healthcare company that appears across podcasts on biotech deals and on healthcare in Asia Pacific. Ahmed Elhusseiny told Analyse Asia with Bernard Leong that it is about 125 years old and has two broad parts, Roche Pharmaceuticals and Roche Diagnostics.
Speakers also discuss its dealmaking. Luke Timmerman said Roche acquired Flatiron Health for $2.1 billion, and a guest on Approved said Blueprint Medicines signed a $775 million partnership with Roche in July 2020. Alex Kesin said Roche returned the Gavreto rights in February 2023 after weak sales. Chris Gibson said Recursion signed a collaboration with Roche and Genentech lasting more than a decade.
16 facts from 5 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2018
Roche acquired Flatiron Health in February for $2.1 billion, according to host Luke Timmerman.
“Flatiron was acquired by Roche in February for $2.1 billion.”
2018
Flatiron has created internal structures to wall off teams so confidential client information is not disclosed to Roche or other clients.
“We cannot disclose any of that information. In fact, have created internal structures to wall off the teams”
2018-2023
Over about five years, Novartis did roughly $100 billion of transactions to exit consumer health and eye care devices, plan the Sandoz spin-off and sell its Roche stake.
“So over the last five years, we've done about $100 billion of transactions to exit consumer health, eye care devices, our planned spin of Sandoz”
2020
Roche partnered with the World Health Organization to allocate one of its products fairly during the pandemic, according to Ahmed Elhusseiny.
“One example is a partnership we did with the WHO to allocate one of our products and to make sure that the allocation of this product is as fair and just as possible.”
2020
In July 2020 Blueprint Medicines signed a $775 million partnership with Roche for pralsetinib (Gavreto).
“In July 2020, Blueprint signs a massive $775 million partnership deal with Roche for Pralcetinib, brand name GAVRETO.”
2023
Roche returned the rights to Gavreto to Blueprint in February 2023 after weak sales.
“So now it's February of 2023. Roche sees that this drug wasn't performing nearly as well as they had hoped. So they end up giving it back to Blueprint.”
Undated
Roche is a Swiss company about 125 years old, according to Ahmed Elhusseiny, with a global footprint including Asia Pacific.
“This is a 125-year-old company. It's a Swiss company, but it's truly a global company with a global footprint, including, of course, in Asia Pacific.”
Undated
Roche's stated mission, per Ahmed Elhusseiny, is doing now what patients need next.
“Our mission is around doing now what patients need next.”
Undated
Ahmed Elhusseiny says Roche's motto is first in class, best in class.
“Our motto is first in class, best in class.”
Undated
Roche consists of two broad parts, Roche Pharmaceuticals and Roche Diagnostics, according to Ahmed Elhusseiny.
“Roche, broadly speaking, is also Roche Pharmaceuticals and Roche Diagnostics.”
Undated
Ahmed Elhusseiny says Roche's presence in Asia spans manufacturing, research and development, commercialization and medical services.
“our presence extends from manufacturing to research and development and, of course, commercialization and medical services to patients all over the region.”
Undated
In Thailand, Roche partnered with local associations to provide COVID testing in remote areas using tuk-tuks.
“in Thailand, we partnered with local associations there to really be able to provide COVID testing in remote areas using tuk-tuks.”
Undated
Ahmed Elhusseiny says personalised healthcare would tailor treatment to a person's genetic profile and background rather than giving everyone the same regimen.
“based on your genetic profile, based on your background, your healthcare, you would get something different based on that than I would.”
Undated
Ahmed Elhusseiny says personalised healthcare combines medical science, digital technology and data science.
“Personalized healthcare brings together medical science, digital technology, and data science.”
Undated
Ahmed Elhusseiny says personalised healthcare would be measurable partly through lower hospitalisation rates and shorter hospital stays.
“we could see people staying shorter periods in hospitals. So hospitalization rates would go down.”
Undated
Recursion signed a collaboration with Roche and Genentech lasting more than a decade, covering neuroscience and one oncology indication.
“In December, almost exactly a year ago, December last year, we signed a huge collaboration with Rosh and Genentech to deploy our technology in partnership with them for more than a decade”
Episodes